GRM5 and gastroesophageal reflux disease: The objective of the current study was to evaluate the effect of the novel metabotropic glutamate receptor 5 antagonist TT001 on gastroesophageal reflux during anaesthesia in dogs using two different protocols.<h4>Materials and methods</h4>One hundred and nineteen client-owned dogs were included and randomly assigned to receive test-drug containing either active TT001 (n = 58) or placebo vehicle (n = 61).